サマリー

Therapies related to the JAK and PI3K signaling pathways have the potential to target diseases such as cancer and inflammatory diseases, and no suitable drugs are currently available. Current therapies can reduce the burden of disease, but they cannot be cured.
Significant progress has been made in understanding the complexity of signaling pathways such as JAK and PI3K over the past few years. At the same time, great progress has been made in the isolation of target-specific therapies / inhibitors targeting abnormal signals in these pathways. After approval of ruxolitinib (for bone marrow fibrosis) and tofacitinib (for rheumatoid arthritis), the treatment of JAK and PI3K cell signaling pathways has focused on cancer lines and inflammatory diseases.

Market Analysis and Insights: Global JAK and PI3K Signaling Pathway Market
The global JAK and PI3K Signaling Pathway market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global JAK and PI3K Signaling Pathway market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global JAK and PI3K Signaling Pathway market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global JAK and PI3K Signaling Pathway market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global JAK and PI3K Signaling Pathway market.

Global JAK and PI3K Signaling Pathway Scope and Market Size
JAK and PI3K Signaling Pathway market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global JAK and PI3K Signaling Pathway market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
PI3K
Janus Kinase Therapies (Inhibitors)
PI3K Therapies (Inhibitors)
Signal Transduction Biomarkers for JAK and PI3K

Segment by Application
Cancer
Inflammatory Diseases
Cardiac Ailments
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer HealthCare Pharmaceuticals
AbbVie
AstraZeneca
Curis
Daiichi Sankyo
Exelixis
Genentech
Infinity Pharmaceuticals
Merck & Co.
Rigel Pharmaceuticals
TG Therapeutics
Sanofi Oncology
Vertex Pharmaceuticals
WILEX AG

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global JAK and PI3K Signaling Pathway Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 PI3K
1.2.3 Janus Kinase Therapies (Inhibitors)
1.2.4 PI3K Therapies (Inhibitors)
1.2.5 Signal Transduction Biomarkers for JAK and PI3K
1.3 Market by Application
1.3.1 Global JAK and PI3K Signaling Pathway Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cancer
1.3.3 Inflammatory Diseases
1.3.4 Cardiac Ailments
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global JAK and PI3K Signaling Pathway Market Perspective (2016-2027)
2.2 JAK and PI3K Signaling Pathway Growth Trends by Regions
2.2.1 JAK and PI3K Signaling Pathway Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 JAK and PI3K Signaling Pathway Historic Market Share by Regions (2016-2021)
2.2.3 JAK and PI3K Signaling Pathway Forecasted Market Size by Regions (2022-2027)
2.3 JAK and PI3K Signaling Pathway Industry Dynamic
2.3.1 JAK and PI3K Signaling Pathway Market Trends
2.3.2 JAK and PI3K Signaling Pathway Market Drivers
2.3.3 JAK and PI3K Signaling Pathway Market Challenges
2.3.4 JAK and PI3K Signaling Pathway Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top JAK and PI3K Signaling Pathway Players by Revenue
3.1.1 Global Top JAK and PI3K Signaling Pathway Players by Revenue (2016-2021)
3.1.2 Global JAK and PI3K Signaling Pathway Revenue Market Share by Players (2016-2021)
3.2 Global JAK and PI3K Signaling Pathway Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by JAK and PI3K Signaling Pathway Revenue
3.4 Global JAK and PI3K Signaling Pathway Market Concentration Ratio
3.4.1 Global JAK and PI3K Signaling Pathway Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by JAK and PI3K Signaling Pathway Revenue in 2020
3.5 JAK and PI3K Signaling Pathway Key Players Head office and Area Served
3.6 Key Players JAK and PI3K Signaling Pathway Product Solution and Service
3.7 Date of Enter into JAK and PI3K Signaling Pathway Market
3.8 Mergers & Acquisitions, Expansion Plans

4 JAK and PI3K Signaling Pathway Breakdown Data by Type
4.1 Global JAK and PI3K Signaling Pathway Historic Market Size by Type (2016-2021)
4.2 Global JAK and PI3K Signaling Pathway Forecasted Market Size by Type (2022-2027)

5 JAK and PI3K Signaling Pathway Breakdown Data by Application
5.1 Global JAK and PI3K Signaling Pathway Historic Market Size by Application (2016-2021)
5.2 Global JAK and PI3K Signaling Pathway Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America JAK and PI3K Signaling Pathway Market Size (2016-2027)
6.2 North America JAK and PI3K Signaling Pathway Market Size by Type
6.2.1 North America JAK and PI3K Signaling Pathway Market Size by Type (2016-2021)
6.2.2 North America JAK and PI3K Signaling Pathway Market Size by Type (2022-2027)
6.2.3 North America JAK and PI3K Signaling Pathway Market Size by Type (2016-2027)
6.3 North America JAK and PI3K Signaling Pathway Market Size by Application
6.3.1 North America JAK and PI3K Signaling Pathway Market Size by Application (2016-2021)
6.3.2 North America JAK and PI3K Signaling Pathway Market Size by Application (2022-2027)
6.3.3 North America JAK and PI3K Signaling Pathway Market Size by Application (2016-2027)
6.4 North America JAK and PI3K Signaling Pathway Market Size by Country
6.4.1 North America JAK and PI3K Signaling Pathway Market Size by Country (2016-2021)
6.4.2 North America JAK and PI3K Signaling Pathway Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe JAK and PI3K Signaling Pathway Market Size (2016-2027)
7.2 Europe JAK and PI3K Signaling Pathway Market Size by Type
7.2.1 Europe JAK and PI3K Signaling Pathway Market Size by Type (2016-2021)
7.2.2 Europe JAK and PI3K Signaling Pathway Market Size by Type (2022-2027)
7.2.3 Europe JAK and PI3K Signaling Pathway Market Size by Type (2016-2027)
7.3 Europe JAK and PI3K Signaling Pathway Market Size by Application
7.3.1 Europe JAK and PI3K Signaling Pathway Market Size by Application (2016-2021)
7.3.2 Europe JAK and PI3K Signaling Pathway Market Size by Application (2022-2027)
7.3.3 Europe JAK and PI3K Signaling Pathway Market Size by Application (2016-2027)
7.4 Europe JAK and PI3K Signaling Pathway Market Size by Country
7.4.1 Europe JAK and PI3K Signaling Pathway Market Size by Country (2016-2021)
7.4.2 Europe JAK and PI3K Signaling Pathway Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific JAK and PI3K Signaling Pathway Market Size (2016-2027)
8.2 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Type
8.2.1 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Type (2016-2021)
8.2.2 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Type (2022-2027)
8.2.3 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Type (2016-2027)
8.3 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Application
8.3.1 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Application (2016-2021)
8.3.2 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Application (2022-2027)
8.3.3 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Application (2016-2027)
8.4 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Region
8.4.1 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Region (2016-2021)
8.4.2 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America JAK and PI3K Signaling Pathway Market Size (2016-2027)
9.2 Latin America JAK and PI3K Signaling Pathway Market Size by Type
9.2.1 Latin America JAK and PI3K Signaling Pathway Market Size by Type (2016-2021)
9.2.2 Latin America JAK and PI3K Signaling Pathway Market Size by Type (2022-2027)
9.2.3 Latin America JAK and PI3K Signaling Pathway Market Size by Type (2016-2027)
9.3 Latin America JAK and PI3K Signaling Pathway Market Size by Application
9.3.1 Latin America JAK and PI3K Signaling Pathway Market Size by Application (2016-2021)
9.3.2 Latin America JAK and PI3K Signaling Pathway Market Size by Application (2022-2027)
9.3.3 Latin America JAK and PI3K Signaling Pathway Market Size by Application (2016-2027)
9.4 Latin America JAK and PI3K Signaling Pathway Market Size by Country
9.4.1 Latin America JAK and PI3K Signaling Pathway Market Size by Country (2016-2021)
9.4.2 Latin America JAK and PI3K Signaling Pathway Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa JAK and PI3K Signaling Pathway Market Size (2016-2027)
10.2 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Type
10.2.1 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Type (2016-2021)
10.2.2 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Type (2022-2027)
10.2.3 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Type (2016-2027)
10.3 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Application
10.3.1 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Application (2016-2021)
10.3.2 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Application (2022-2027)
10.3.3 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Application (2016-2027)
10.4 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Country
10.4.1 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Country (2016-2021)
10.4.2 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer HealthCare Pharmaceuticals
11.1.1 Bayer HealthCare Pharmaceuticals Company Details
11.1.2 Bayer HealthCare Pharmaceuticals Business Overview
11.1.3 Bayer HealthCare Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.1.4 Bayer HealthCare Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.1.5 Bayer HealthCare Pharmaceuticals Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie JAK and PI3K Signaling Pathway Introduction
11.2.4 AbbVie Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.2.5 AbbVie Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca JAK and PI3K Signaling Pathway Introduction
11.3.4 AstraZeneca Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.3.5 AstraZeneca Recent Development
11.4 Curis
11.4.1 Curis Company Details
11.4.2 Curis Business Overview
11.4.3 Curis JAK and PI3K Signaling Pathway Introduction
11.4.4 Curis Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.4.5 Curis Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo JAK and PI3K Signaling Pathway Introduction
11.5.4 Daiichi Sankyo Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.5.5 Daiichi Sankyo Recent Development
11.6 Exelixis
11.6.1 Exelixis Company Details
11.6.2 Exelixis Business Overview
11.6.3 Exelixis JAK and PI3K Signaling Pathway Introduction
11.6.4 Exelixis Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.6.5 Exelixis Recent Development
11.7 Genentech
11.7.1 Genentech Company Details
11.7.2 Genentech Business Overview
11.7.3 Genentech JAK and PI3K Signaling Pathway Introduction
11.7.4 Genentech Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.7.5 Genentech Recent Development
11.8 Infinity Pharmaceuticals
11.8.1 Infinity Pharmaceuticals Company Details
11.8.2 Infinity Pharmaceuticals Business Overview
11.8.3 Infinity Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.8.4 Infinity Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.8.5 Infinity Pharmaceuticals Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. JAK and PI3K Signaling Pathway Introduction
11.9.4 Merck & Co. Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.9.5 Merck & Co. Recent Development
11.10 Rigel Pharmaceuticals
11.10.1 Rigel Pharmaceuticals Company Details
11.10.2 Rigel Pharmaceuticals Business Overview
11.10.3 Rigel Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.10.4 Rigel Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.10.5 Rigel Pharmaceuticals Recent Development
11.11 TG Therapeutics
11.11.1 TG Therapeutics Company Details
11.11.2 TG Therapeutics Business Overview
11.11.3 TG Therapeutics JAK and PI3K Signaling Pathway Introduction
11.11.4 TG Therapeutics Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.11.5 TG Therapeutics Recent Development
11.12 Sanofi Oncology
11.12.1 Sanofi Oncology Company Details
11.12.2 Sanofi Oncology Business Overview
11.12.3 Sanofi Oncology JAK and PI3K Signaling Pathway Introduction
11.12.4 Sanofi Oncology Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.12.5 Sanofi Oncology Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Details
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.13.4 Vertex Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 WILEX AG
11.14.1 WILEX AG Company Details
11.14.2 WILEX AG Business Overview
11.14.3 WILEX AG JAK and PI3K Signaling Pathway Introduction
11.14.4 WILEX AG Revenue in JAK and PI3K Signaling Pathway Business (2016-2021)
11.14.5 WILEX AG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details